Daniel's ATM inhibitor + fenofibrate paper accepted!

Congratulations to Daniel and co-authors Raquel, Erika, and Kelly for the acceptance of this pandemic-derived paper! Daniel had an interesting observation that ATM status corresponds to metabolic gene signatures, and inhibition of ATM in high grade serous ovarian cancer (usually ATM wildtype) synergizes with the FDA-approved metabolic drug fenofibrate.